Laidlaw acts as Sole-Book Runner on the $3,500,000 BioSig Technologies’ Follow-On Transaction.

Laidlaw Capital Markets is pleased to have acted as Sole-Book Runner on the $3,500,000 Common Stock transaction for BioSig Technologies (BSGM).

Read Article
Laidlaw acts as Sole-Book Runner on the $3,500,000 BioSig Technologies’ Follow-On Transaction.2022-06-28T13:29:47+00:00

Laidlaw acts as Underwriter on the $367,886,900 Cohen & Steers Real Estate Opportunities and Income Fund Offering

Laidlaw Capital Markets is pleased to have acted as Underwriter on the $367,886,900 Cohen & Steers Real Estate Opportunities and Income Fund Offering alongside Bank of America, Morgan Stanley, Raymond James, UBS, & Wells Fargo.

Read article: https://www.prnewswire.com/news-releases/cohen–steers-real-estate-opportunities-and-income-fund-rlty-raises-305-million-301490198.html

 

 

 

Laidlaw acts as Underwriter on the $367,886,900 Cohen & Steers Real Estate Opportunities and Income Fund Offering2022-03-30T17:06:36+00:00

Laidlaw Capital Markets acts as Co-Lead Bookrunner on Cingulate Inc’s (CING) $25,000,000 Offering.

Laidlaw Capital Markets is pleased to have been Co-Lead Bookrunner on Cingulate Inc’s (CING) $25,000,000 Offering. Cingulate utilizes its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation products.

Read Article: https://finance-yahoo-com.cdn.ampproject.org/c/s/finance.yahoo.com/amphtml/news/cingulate-inc-announces-pricing-25-020500801.html

 

Laidlaw Capital Markets acts as Co-Lead Bookrunner on Cingulate Inc’s (CING) $25,000,000 Offering.2022-01-06T15:45:44+00:00

Laidlaw Capital Markets is Financial Advisor on MEI Pharma Inc’s $52,325,000 Follow-On Offering

Laidlaw Capital Markets is pleased to be Financial Advisor on the MEI Pharma Inc’s $52,325,000 Follow-On Offering alongside Jefferies, Stifel, and Wells Fargo.”
Laidlaw Capital Markets is Financial Advisor on MEI Pharma Inc’s $52,325,000 Follow-On Offering2022-01-10T05:30:29+00:00

Laidlaw Capital Markets is Financial Advisor on EyePoint Pharmaceuticals Inc’s $115,400,000 Follow-On Offering.

Laidlaw Capital Markets is pleased to be Financial Advisor on the EyePoint Pharmaceutical Inc’s $115,400,000 Follow-On Offering alongside Cowen and Guggenheim Securities
Laidlaw Capital Markets is Financial Advisor on EyePoint Pharmaceuticals Inc’s $115,400,000 Follow-On Offering.2022-01-10T05:34:18+00:00

Laidlaw Capital Markets is pleased to have acted as Sole Book-Runner on the $10,000,000 Follow-On Offering for BioSig Technologes (BSGM).

The Laidlaw Capital Markets team is pleased to announce our role as Sole Book-Runner and the pricing of a $10,000,000 Follow-on Offering for BioSig Technologies (BSGM). We are proud to have raised approximately $40,000,000 for BioSig over the course of our decade long relationship and look forward to watch the company continue to execute.

Read Article: https://ir.biosig.com/press-releases/detail/278/biosig-announces-closing-of-public-offering-of-common-stock

Laidlaw Capital Markets is pleased to have acted as Sole Book-Runner on the $10,000,000 Follow-On Offering for BioSig Technologes (BSGM).2021-07-12T10:13:09+00:00

How advisor platforms are changing the offshore industry

Independent advisor platforms are attracting a growing number of international advisors to their networks. What is driving this growth and what are the benefits for advisors who opt for this independent model?

The entrepreneurial spirit is strong in the advisory industry, with a growing number of international advisors now making the jump to independence. But launching an RIA can prove a time-consuming and costly venture that also requires negotiating crucial third-party agreements with a range of service providers.

Read Full Article Here

How advisor platforms are changing the offshore industry2021-07-07T03:33:04+00:00
Go to Top